Is Selinexor a targeted drug?

Selinexor (Selinexor) is an orally bioavailable, selective inhibitor of nuclear export compounds that inhibits the novel therapeutic targetexportin-1 (XPO1), which is overexpressed in multiple myeloma (MM) and is responsible for the transport of nuclear proteins to the cytoplasm, including tumor suppressor proteins. Inhibition of this process has shown significant antimyeloma activity in preclinical studies, either alone or in combination with established multiple myeloma therapies. Therefore, selinesol is a type of targeted drug.

Targeting XPO1 in Multiple Myeloma The rationale for XPO1 mirrors that in other tumor types, where XPO1 has been shown to be overexpressed. Based on a clinical trial program that includes multiple combination regimens, selinesol-based therapy has been approved for the treatment of relapsed/refractory multiple myeloma (R/R MM), Selinesol-dexamethasone is approved for late relapse in patients refractory to penta-drug therapy, and selinesol-bortezomib-dexamethasone is approved for patients who have received ≥1 prior therapy.

The original drug Seleniso has been launched in China, but it has not yet entered the scope of medical insurance. Specifications The price of 20mg*12 tablets per box may be around 20,000 yuan. The US version of the original Seleniso drug sold overseas, with a specification of 20mg*8 tablets, may cost more than 100,000 yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are also generic Selinisol drugs produced and marketed overseas. The price of a box of 20mg*16 tablets produced by a Lao pharmaceutical factory may be around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the original drugs sold domestically and abroad.